In leukemic and myeloma systems, CaMKIIγ sustains NF-κB, β-catenin, STAT3, and ERK signaling, reinforcing stem-like properties and creating a permissive environment for therapy escape [66,67,78]. The gene discussed is STAT3; the disease is plasma cell myeloma.